C5 nephritic factors drive the biological phenotype of C3 glomerulopathies

Kidney International

Volumn 92, Issue 5, 2017, Pages 1232-1241

  Marinozzi, Maria Chiara ^a,b   Chauvet, Sophie ^a,b   Le Quintrec, Moglie ^c   Mignotet, Morgane ^a,b   Petitprez, Florent ^b   Legendre, Christophe ^d   Cailliez, Mathilde ^e   Deschenes, Georges ^f   Fischbach, Michel ^g   Karras, Alexandre ^a   Nobili, Francois ^h   Pietrement, Christine ⁱ   Dragon Durey, Marie Agnes ^a,b   Fakhouri, Fadi ^j   Roumenina, Lubka T ^b   Fremeaux Bacchi, Veronique ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ REIMS UNIVERSITY HOSPITAL   (France)

^j Service de Néphrologie   (France)

more..

Author keywords

complement; membranoproliferative glomerulonephritis; nephritic factor

Indexed keywords

AUTOANTIBODY; C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; IMMUNOGLOBULIN G; NEPHRITIC FACTOR; PROPERDIN; UNCLASSIFIED DRUG; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT MEMBRANE ATTACK COMPLEX; SC5B-9 PROTEIN COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSE DEPOSIT DISEASE; ENZYME STABILITY; FEMALE; GENETIC VARIATION; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; BLOOD; FOLLOW UP; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METABOLISM; MIDDLE AGED; MORTALITY; PHENOTYPE; SEROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENOTYPE; PROPERDIN; SEROLOGIC TESTS; YOUNG ADULT;

EID: 85023606268     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.04.017     Document Type: Article

References (29)

1. Pickering, M.C., D'Agati, V.D., Nester, C.M., et al. C3 glomerulopathy: consensus report. Kidney Int 84 (2013), 1079–1089.
2. Cook, H.T., Pickering, M.C., Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 11 (2015), 14–22.
3. Sethi, S., Fervenza, F.C., Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med 366 (2012), 1119–1131.
4. Servais, A., Noel, L.H., Roumenina, L.T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
5. Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., et al. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol, 6, 2015, 262.
6. Lesher, A.M., Nilsson, B., Song, W.C., Properdin in complement activation and tissue injury. Mol Immunol 56 (2013), 191–198.
7. Berends, E.T., Gorham, R.D. Jr., Ruyken, M., et al. Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. BMC Biol, 13, 2015, 93.
8. Daha, M.R., Fearon, D.T., Austen, K.F., C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116 (1976), 1–7.
9. Mollnes, T.E., Ng, Y.C., Peters, D.K., et al. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol 65 (1986), 73–79.
10. Zhang, Y., Nester, C.M., Martin, B., et al. Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol 9 (2014), 1876–1882.
11. Corvillo, F., Garcia-Morato, M.B., Nozal, P., et al. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol 184 (2016), 118–125.
12. Varade, W.S., Forristal, J., West, C.D., Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis 16 (1990), 196–206.
13. Tanuma, Y., Ohi, H., Hatano, M., Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 56 (1990), 226–238.
14. Clardy, C.W., Forristal, J., Strife, C.F., et al. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 50 (1989), 333–347.
15. Lesher, A.M., Zhou, L., Kimura, Y., et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol 24 (2013), 53–65.
16. Ruseva, M.M., Vernon, K.A., Lesher, A.M., et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 24 (2013), 43–52.
17. Paixao-Cavalcante, D., Lopez-Trascasa, M., Skattum, L., et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 82 (2012), 1084–1092.
18. Zhang, Y., Meyer, N.C., Wang, K., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7 (2012), 265–274.
19. Fischer, E., Kazatchkine, M.D., Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol 130 (1983), 2821–2824.
20. Hourcade, D.E., The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem 281 (2006), 2128–2132.
21. Bajic, G., Degn, S.E., Thiel, S., et al. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J 34 (2015), 2735–2757.
22. Fervenza, F.C., Sethi, S., Circulating complement levels and C3 glomerulopathy. Clin J Am Soc Nephrol 9 (2014), 1829–1831.
23. De Vriese, A.S., Sethi, S., Van Praet, J., et al. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol 26 (2015), 2917–2929.
24. Bu, F., Borsa, N.G., Jones, M.B., et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27 (2016), 1245–1253.
25. Iatropoulos, P., Noris, M., Mele, C., et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71 (2016), 131–142.
26. Nasr, S.H., Valeri, A.M., Appel, G.B., et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4 (2009), 22–32.
27. Rabasco, C., Cavero, T., Roman, E., et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88 (2015), 1153–1160.
28. Goodship, T.H., Cook, H.T., Fakhouri, F., et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91 (2017), 539–551.
29. Morgan, B.P., Harris, C.L., Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 14 (2015), 857–877.